Ambulatory Blood Pressure Monitoring (ABPM)

Technique, normal values, and physiological phenomena

• MAPA technique and measurement conditions : equipment: validated oscillometric cuff + portable recorder → cuff placed on non-dominant arm (or dominant if significant difference between the two arms >10 mmHg - in this case use the arm with the highest BP) → cuff size adapted to arm circumference (cuff too small overestimates BP + too large underestimates it) → programming : measurements every 15-30 min during the day + every 30-60 min at night → minimum duration: 24h + valid recordings: at least 70 % of valid measurements + minimum 14 daytime measurements + minimum 7 nighttime measurements → instructions to the patient: normal activities of daily living + keep a diary (activities + medication intake + symptoms + bedtime and wake-up time) → keep arm still and relaxed during measurement → do not remove cuff → driving possible but immobilize arm + MAPA diagnostic values - hypertension thresholds: diurnal mean ≥135/85 mmHg = diurnal hypertension → nocturnal mean ≥120/70 mmHg = nocturnal hypertension → 24h mean ≥130/80 mmHg = 24h hypertension → recall office measurement: ≥140/90 mmHg = HTA + nocturnal dipping: blood pressure physiologically decreases at night by 10-20 % compared with the diurnal average → called dippers → non-dippers: nocturnal decrease <10 % → surdipper : baisse nocturne>20 % → reverse dipper (riseur) : Nocturnal BP > Diurnal BP → significant cardiovascular prognostic value: non-dipper and reverse dipper → increased cardiovascular and renal risk
• Physiological phenomena and particular tension profiles: Physiological phenomena measured by ABPM: Blood pressure variability: normal fluctuations in BP depending on physical activity + emotions + stress + postural changes → Morning surge in BP: sudden increase in BP upon waking → associated with the risk of morning stroke and heart attack → Alarm phenomenon (white coat effect) → White coat hypertension (WCH): BP ≥140/90 in the doctor's office + but normal ABPM (daytime) <135>

  Indications, interpretation, and therapeutic implications

  Appearance / indication	Data, interpretation, and plan of action	References and recommendations
  MAPA indications and table of threshold values Indications Diagnosed hypertension in office — White coat hypertension suspected — Masked hypertension — Resistant hypertension — Treatment evaluation — Nocturnal hypertension Sleep apnea syndrome (SAS) — Pregnancy — Chronic kidney disease (CKD) — Type 1 diabetes (DT1) Type 2 diabetes (DT2) — Labile hypertension — Cardiovascular risk assessment — Hypertension Canada 2024 — Ambulatory blood pressure monitoring (ABPM) vs. home blood pressure monitoring (HBPM)	Recommended indications for ABPM (Hypertension Canada 2024 + INESSS Québec): validated indications for ABPM: confirmation of the diagnosis of hypertension if in doubt (office BP 130-180/85-110 mmHg) → avoids over-diagnosis and under-diagnosisdiagnosis + suspicion of white coat hypertension (high BP in the office + anxious patient + normal BP at home) + suspicion of masked hypertension (borderline BP in the office + risk factors + target organ damage without confirmed hypertension in the office) + assessment of resistant resistant (poorly controlled BP despite ≥3 antihypertensive agents, including a diuretic) → exclude BBH + optimize treatment + assess therapeutic effect (24-hour blood pressure monitoring - validate nadir and peak action of medication) + nocturnal hypertension : sleep apnea syndrome (SAS) + CKD + diabetes + suspected nocturnal hypertension + pregnancy: screening for pre-eclampsia + blood pressure monitoring + labile hypertension + syncope + unexplained vertigo → summary table of diagnostic thresholds: Office BP: <130/85 = normal + 130-139/85-89 = high normal + ≥140/90 = HTA + Daytime (awake) ABPM: <130/80 = normal + ≥135/85 = HTA + Nocturnal (sleep) ABPM: <115/65 = normal + ≥120/70 = nocturnal HTA + 24h ABPM: <125/75 = normal + ≥130/80 = HTA + MPAD (home measurement): <130/80 = normal + ≥135/85 = HTA → agreement Hypertension Canada 2024 + ESH 2023 + ACC/AHA 2023 + ABPM vs MPAD: MAPA superior if: nocturnal profile required + nocturnal masked hypertension suspected + SAS + CKD + pregnancy + MPAD preferred if: long-term follow-up + accessibility + limited RAMQ reimbursement	Hypertension Canada 2024 guidelines: Ambulatory Blood Pressure Monitoring (ABPM) + indications + thresholds → current Canadian reference + Williams 2018 — JAMA: ABPM + CV risk prediction → superior to office measurement + Bobrie 2004 — JAMA: masked hypertension + ABPM + CV risk + Hansen 2006 — Circulation: masked hypertension + CV events + Dolan 2005 — Hypertension: ABPM + dipping + prognosis + ESH 2023 guidelines: ABPM + hypertension + European thresholds + ACC/AHA 2023 + INESSS Quebec + RAMQ: ABPM → reimbursed according to medically justified indications
  Clinical Interpretation and Therapeutic Implications Sustained hypertension pharmacological treatment — White coat hypertension no immediate treatment — Masked hypertension treat as sustained hypertension — Nocturnal non-dipper treatment in the evening — Excessive nocturnal dipping over-dipper — Morning hypertension — Blood pressure targets — Treatment titration — Hypertension Canada — ACTH chronotherapy	ABPM interpretation and therapeutic implications: sustained hypertension (elevated ABPM + elevated office BP): pharmacological treatment indicated according to overall cardiovascular risk + comorbidities (CKD + T2DM + stroke + coronary artery disease) → blood pressure targets: <135/85 mmHg daytime ambulatory + or <130/80 mmHg over 24h → white coat hypertension (normal ABPM + elevated office BP): hygienic-dietary measures (HDM) → sodium reduction + physical activity + weight + alcohol → annual ABPM monitoring → pharmacological treatment deferred if no target organ damage (LVH + proteinuria + CKD) → but rigorous monitoring as BBH may evolve into sustained hypertension → masked hypertension (high ABPM + normal office BP): pharmacological treatment recommended even if office BP is normal → because cardiovascular risk is equivalent to sustained hypertension → Bobrie 2004 - JAMA + Hansen 2006 - Circulation + non-dipper profile (nocturnal fall <10 %): optimize antihypertensive treatment → shift medication intake to bedtime (chronotherapy) → treat underlying causes (SAS → CPAP + CKD + TD + heart failure) → ACCORD trial 2010 - NEJM: intensive blood pressure targets (<120/80 mmHg) in T2DM → no benefit on CV mortality vs standard (<140/90) → but SPRINT 2015 - NEJM: intensive target (20 %): risk of nocturnal ischemia (stroke + nocturnal infarction) if antihypertensive treatment too powerful → adapt nocturnal dosage → inverse dipper (nocturnal BP > diurnal BP): associated with risk of stroke + CKD + diabetes → look for and treat causes (SAS +++ + CKD + heart failure + diabetes)→ optimize chronotherapy + morning surge (morning increase): 24-hour antihypertensive coverage → check that the drug covers the morning period	Bobrie 2004 — JAMA: Masked hypertension + ABPM + CV risk → reference + Hansen 2006 — Circulation: Masked hypertension + CV + SPRINT 2015 — NEJM: Intensive target <120 mmHg non-DM → 25% reduction % CV events + ACCORD 2010 — NEJM: Intensive target DM2 → no CV mortality benefit + Dolan 2005 — Hypertension: Dipping + CV and renal prognosis → Williams 2018 — JAMA: ABPM + CV risk + Hypertension Canada 2024: Masked hypertension + LMWH + treatment → INESSS Quebec + RAMQ: Antihypertensive medications → reimbursed according to indications
  MAP in specific contexts – pregnancy, CKD, OSA MAPA preeclampsia — nocturnal hypertension CKD — MAPA T1D T2D — OSA sleep apnea nocturnal hypertension — MAPA child adolescent — MAPA elderly orthostatic hypotension — MAPA resistant hypertension — MAPA elderly white coat hypertension — false positives — cuff deflation — RAMQ reimbursement	ABPM in special contexts: pregnancy - pre-eclampsia and gestational hypertension: ABPM very useful for distinguishing true gestational hypertension from white coat hypertension (frequent in pregnancy) + monitoring of nocturnal blood pressure profile (loss of nocturnal dipping = early sign of pre-eclampsia) → diagnostic thresholds in pregnancy: 24h ABPM ≥130/80 mmHg → target under treatment: 130-150/80-100 mmHg → methyldopa + labetalol + nifedipine retard (safe drugs in pregnancy) + chronic renal failure (CKD): frequent non-dipper profile + nocturnal hypertension → MAPA essential to optimize treatment + blood pressure target <130/80 mmHg (or 1 g/d) + ACEI or ARB (nephroprotection + proteinuria reduction) + iGLT2 (dapagliflozin + empagliflozin) if eGFR ≥20 → CKD progression reduction + sleep apnea syndrome (SAS) and nocturnal hypertension: SAS → activation of the sympathetic nervous system at night → nocturnal hypertension + non-dipper or inverse-dipper profile → Hypertension Canada: look for and treat SAS (CPAP - continuous positive airway pressure) + CPAP improves nocturnal blood pressure profile → Pepin 2009 - Hypertension: CPAP + SAS + nocturnal hypertension → nocturnal BP reduction + type 1 and type 2 diabetes : ABPM - screening for masked hypertension and nocturnal hypertension (frequent) + nocturnal hypertension associated with risk of albuminuria + diabetic CKD + retinopathy + ABPM in the elderly: frequent orthostatic hypotension (BP falling by ≥20/10 mmHg within 3 min of rising) → risk of falls + fractures → positional assessment + adapt treatment (reduce diuretics + alpha-blockers if severe orthostatic hypotension)	Hypertension Canada 2024: Ambulatory Blood Pressure Monitoring (ABPM) + pregnancy + Chronic Kidney Disease (CKD) + Sleep Apnea Syndrome (SAS) → recommendations + Pepin 2009 – Hypertension: Positive Pressure Ventilation (PPV) + SAS + nocturnal hypertension → blood pressure reduction + Fagard 2009 – Journal of Hypertension: dipping + CKD + renal risk + Williams 2018 – JAMA: ABPM + superior + cardiovascular risk + ESH 2023 guidelines: ABPM + pregnancy + SAS + CKD + Cheung 2012 – Diabetologia: ABPM + Type 1 Diabetes (T1D) + nocturnal hypertension → renal risk + INESSS Quebec + RAMQ: ABPM → reimbursed + specific indications: CKD + pregnancy + SAS + resistant hypertension

  ℹ️ The MAPA is the gold standard test for confirming a diagnosis of hypertension—it is superior to in-office measurements for predicting cardiovascular events: Diagnostic thresholds are 135/85 mmHg daytime and 130/80 mmHg over 24 hours. Masked hypertension (normal office BP but high ABPM) is as dangerous as sustained hypertension, and requires treatment. A non-dipper profile (no nocturnal drop in BP) is associated with increased cardiovascular and renal risk - look for sleep apnea syndrome or CKD.
  Situations requiring urgent or priority care

  MAP reveals an average 24h BP ≥180/110 mmHg or very high nocturnal BP (>170/100 mmHg) without antihypertensive treatment in place → sustained severe hypertension → urgent initiation of antihypertensive treatment + work-up of repercussions (fundus + creatinine + proteinuria + ECG + LVH on echo) → if symptoms (headache + confusion + dyspnea + chest pain) → emergencies → hypertensive hypertension with target organ damage.

  MAP in pregnancy reveals nocturnal BP >135/85 mmHg + patient with proteinuria (>300 mg/day) + headaches + or significant edema + or elevated transaminases → preeclampsia → obstetric emergency → HELLP workup (LDH + AST + platelets) + urgent obstetric consultation + antihypertensives suitable for pregnancy (labetalol + nifedipine) + magnesium sulfate if eclampsia.

  MAPA reveals an inverse-dipper profile (nighttime BP > daytime BP) + or severe nocturnal hypertension in a patient complaining of snoring + reported apneas + excessive daytime sleepiness + morning fatigue → probable sleep apnea syndrome (SAS) → polysomnography + or screening test (ApneaLink + Nox T3) → CPAP if SAS confirmed → SAS treatment improves nocturnal blood pressure profile.

  Consult at Clinique Omicron

  Clinique Omicron physicians prescribe and interpret ABPM, differentiate sustained hypertension from white-coat hypertension and masked hypertension, detect non-dipper and reverse-dipper profiles, initiate or adapt antihypertensive treatment accordingly (chronotherapy + blood pressure targets adapted for CKD + pregnancy + diabetes), screen for sleep apnea syndrome in patients with pathological nocturnal profiles, and provide long-term blood pressure monitoring via ABPM or self-measurement. Consultations are available at several service points in Quebec and via telemedicine. To book an appointment, visit cliniqueomicron.ca.

  The content on this page is for informational purposes only and does not substitute for the advice of a doctor or a specialist in arterial hypertension. The interpretation of ABPM should always be made within the complete clinical context of the patient — threshold values are guidelines and not absolute dogmas.